首页> International journal of clinical oncology> C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab

C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab

导出原文传递

翻译打印收藏纠错

第一作者： Suzuki, Kotaro

作者： Suzuki, Kotaro ^[1] ; Terakawa, Tomoaki ; Furukawa, Junya ; Harada, Kenichi ; Hinata, Nobuyuki ; Nakano, Yuzo ; Fujisawa, Masato

作者单位： Kobe Univ, Div Urol, Grad Sch Med, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan ^[1]

关键词 Metastatic renal cell carcinoma (mRCC)Nivolumab Immune checkpoint inhibitor (ICI)Neutrophil-to-lymphocyte ratio (NLR)C-reactive protein (CRP)Overall survival (OS)

发布时间 2020-06-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

International journal of clinical oncology

2020年25卷1期

135-144页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览2

International journal of clinical oncology

2020年25卷1期

135-144页

检索历史清除

C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab

International journal of clinical oncology

相似文献

同项目论文

International journal of clinical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab

International journal of clinical oncology

相似文献

同项目论文

International journal of clinical oncology

相关期刊

检索历史清除